The specific reason is that CADM1 is downregulated in most cases due to its promoter methylation as well as being related to the progression of malignant tumors, advanced classification, poor 5-year survival, and high recurrence rate; for example, in cervical cancer, CADM1 can be used as a biomarker to participate in the assessment of cervical epithelial lesions (Del Pino et al., 2019; El Aliani et al., 2021). Here, CADM1 is linked to cancer.